BTIG Research resumed coverage on Arcus Biosciences with a new price target
$RCUS
Biotechnology: Pharmaceutical Preparations
Health Care
BTIG Research resumed coverage of Arcus Biosciences with a rating of Buy and set a new price target of $57.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2025 | $18.00 → $24.00 | Neutral → Buy | H.C. Wainwright |
| 10/21/2024 | $20.00 | Neutral | H.C. Wainwright |
| 10/8/2024 | $29.00 | Overweight | Wells Fargo |
| 11/18/2022 | $33.00 | Neutral | BofA Securities |
| 10/11/2022 | $40.00 | Overweight | Morgan Stanley |
| 11/19/2021 | $42.00 → $53.00 | Buy | Citigroup |
| 11/19/2021 | $48.00 → $60.00 | Overweight | Barclays |
| 11/18/2021 | $68.00 → $100.00 | Outperform | SVB Leerink |